Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach (Q73127274)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10539397%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10539397%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

P Fenn

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10539397%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

A Gray

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10539397%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 August 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10539397%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10539397%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10539397%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10539397%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

165-174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10539397%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00019053-199916020-00005

1 November 2019

exact match

0 references

cites work

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

12 December 2020

Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease.

1 reference

12 December 2020

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

12 December 2020

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

1 reference

12 December 2020

Cognitive function and the costs of Alzheimer disease. An exploratory study

1 reference

12 December 2020

The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

1 reference

12 December 2020

Modelling programme costs in economic evaluation

1 reference

12 December 2020

1 reference

12 December 2020

Alzheimer's disease: the burden of the illness in England.

1 reference

12 December 2020

A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

1 reference

12 December 2020